PATH welcomes Dr. Lutz Hegemann to the board of directors

Media contact: Lindsay Bosslet | media@path.org

July 7, 2021 – PATH’s board of directors is pleased to welcome Dr. Lutz Hegemann as its newest member. Dr. Hegemann will bring a unique mix of private-sector, research, and medical experience to the board.

“As we embark on the new PATH Strategy 2025, the board has a critical role in overseeing its implementation and supporting the global team in shaping the future of this organization,” said David King, chair of PATH’s board of directors. “We are fortunate to have Dr. Lutz join us at this pivotal moment. His expertise, experience, and perspective will be invaluable for PATH in the years ahead.”

Dr. Lutz Hegemann currently serves as the Group Head of Corporate Affairs and Global Health at Novartis International, where he is responsible for driving forward the corporate strategy of Novartis and integrating global health and environmental, social, and governance matters into the core of the business. He previously held the position of Chief Operating Officer for Global Health at Novartis. Dr. Hegemann has worked at Novartis since 2005 in roles of increasing responsibility.

Dr. Hegemann is a Fellow of the Royal Society of Tropical Medicine and Hygiene. In addition his role on PATH’s board of directors, he also serves on the boards of the Novartis Foundation, the Swiss Alliance against Neglected Tropical Diseases, and the Tanzania Training Centre for International Health.

Dr. Hegemann received an MD and PhD in molecular pharmacology from Utrecht University.